The UK is to embark on a universal campaign to vaccinate the elderly with Sanofi Pasteur MSD's Zostavax vaccine against shingles.
Shingles is the infection of nerve cells with the varicella zoster virus, and the painful condition is particularly prevalent in individuals aged over 70. To reduce the burden of disease in the country, the UK's Joint Committee on Vaccination and Immunisation (JCVI) has recommended that the country should undertake universal routine herpes zoster vaccination for adults in their 70s, commencing in September. Initially, because of levels of availability of the vaccine, only those adults aged 70 and 79 will be offered Zostavax. Around 800,000 people will be eligible for the shingles vaccine in the first year.
According to Public Health England, the Sanofi Pasteur MSD vaccine Zostavax is the recommended vaccine – and the only authorised shingles shot in the UK.
Read more at BBC >
What do you think? Leave a comment in the box below, or on our LinkedIn group discussion.
Sign up to the Vaccine Nation newsletter for more insights into strategy and innovation in vaccines.
If you want to know more about vaccines, and meet innovators, disruptors and influencers from across the vaccine research, development and technology landscape, find out about the World Vaccine Congress Europe 2013, 16-17 October 2013, Lille. Download the brochure >